Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alprostadil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 known ✓ | P43116 | 4/20 | 1.00 |
| ▸ | PTGER1 known ✓ | P34995 | 1/20 | 0.73 |
| ▸ | PTGIR | P43119 | 9/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 3/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alprostadil SCHEMBL5303767 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL12987687 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL11695818 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL11864105 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL23353047 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL7742103 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL23353103 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL23352905 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL22425786 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL11863995 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022164850-A1 | COMPOUNDS TO PREVENT OR TREAT SARS-CoV-2 VARIANT INFECTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-08-04 | — | — | WO | claimed |
| EP-4055007-A1 | PROSTAGLANDIN ANALOGS AND USES THEREOF | Lifex Biolabs, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022164850-A1 | COMPOUNDS TO PREVENT OR TREAT SARS-CoV-2 VARIANT INFECTION | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20210139435-A1 | PROSTAGLANDIN ANALOGS AND USES THEREOF | Lifex Biolabs, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139435-A1 | PROSTAGLANDIN ANALOGS AND USES THEREOF | PTGDR, NR3C1, PTGIR | PTGER2 18/4885PTGER1 5/4885PTGIR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.